Fig. 1
From: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
NSC-311068 and NSC-370284 suppress the viability of AML cells with high TET1 level. a, b TET1-high AML cell lines including MONOMAC-6, THP-1, KOCL-48, and KASUMI-1, along with a TET1-low control cell line (i.e., NB4), were treated with NSC-311068 (a), or NSC-370284 (b), at indicated doses (0, 50, 200, 500 nM). Cell viability was analyzed by MTS 48 h post treatment. c Repression of TET1 expression by NSC-311068 and NSC-370284 in AML cell lines. Cells were treated with DMSO, or 300 nM NSC-311068 or NSC-370284. TET1 expression levels were detected by qPCR 48 h post treatment. d NSC-311068 and NSC-370284 (both at 300 nM) repressed global 5hmC level in THP-1 (left panels) and MONOMAC-6 (right panels) cells. e, f MONOMAC-6, THP-1, and KOCL-48 cells were treated with DMSO, or 25 nM NSC-311068 or NSC-370284. TET1 expression levels (e), and cell viability (f), were detected 24 h post treatment. *P < 0.05, two-tailed t-test. MMC-6, MONOMAC-6. Error bar indicates SD of triplicate experiments
